GLP1R and metabolic dysfunction-associated steatotic liver disease: The review highlighted improvements with pioglitazone and lanifibranor (PPAR agonists), as well as with liraglutide and semaglutide (GLP-1R agonists), showing improvements in hepatic steatosis and lobular inflammation, and in some cases, resolution of NAFLD without exacerbating fibrosis [18].